Hillstar Bio Launches with $67 Million Series A Financing to Develop Next Wave of Precision Immunotherapies to Transform Autoimmune Treatment
- Editor
- Mar 25
- 1 min read
Whats Happening:
Hillstar Bio, a biotechnology company focused on developing precision immunology therapies for autoimmune diseases, has successfully closed a $67 million Series A financing round. The funding will support the advancement of the company's lead TRBV9 program through clinical proof-of-concept studies in axial spondyloarthritis and the expansion of its broader pipeline.
Key Moves:
Hillstar Bio secures $67 million in Series A financing
Funding to advance lead TRBV9 program into clinical trials in 2026
Company aims to selectively deplete pathogenic immune cells in autoimmune diseases
By The Numbers:
$67 million raised in Series A financing
Clinical trials for lead program to begin in 2026
Targeting TRBV9+ T cells in axial spondyloarthritis and other HLA-B27 associated conditions
Key Quotes:
"The interplay between HLA-B27 and TRBV9+ T cells in autoimmune conditions like AxSpA offers a unique opportunity for our lead program," said Robert Mabry, CEO of Hillstar Bio.
"Hillstar Bio has the critical elements necessary to transform autoimmune disease treatment, including top-tier antibody engineering capabilities, a deep understanding of immune cell biology, and an exceptional team of scientists, industry leaders, and advisors," said Luc Dochez, Executive Chair at Hillstar Bio.
Bottom Line:
Hillstar Bio's successful $67 million Series A financing positions the company to advance its innovative approach to autoimmune disease treatment. By selectively targeting pathogenic immune cells, Hillstar Bio aims to provide more durable and effective therapies compared to traditional immunosuppressive treatments, potentially transforming patient outcomes in conditions like axial spondyloarthritis.
תגובות